US 11,981,932 B2
Materials and methods for the manufacture of pluripotent stem cells
Iqbal S. Grewal, Newtown, PA (US); Rajkumar Ganesan, Blue Bell, PA (US); and Sanjaya Singh, Blue Bell, PA (US)
Assigned to JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed by JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed on Jun. 16, 2021, as Appl. No. 17/349,328.
Claims priority of provisional application 63/040,392, filed on Jun. 17, 2020.
Claims priority of provisional application 63/040,397, filed on Jun. 17, 2020.
Claims priority of provisional application 63/040,398, filed on Jun. 17, 2020.
Claims priority of provisional application 63/040,373, filed on Jun. 17, 2020.
Claims priority of provisional application 63/040,374, filed on Jun. 17, 2020.
Prior Publication US 2021/0395697 A1, Dec. 23, 2021
Int. Cl. C12N 5/074 (2010.01); A61K 35/545 (2015.01); C12N 15/86 (2006.01)
CPC C12N 5/0696 (2013.01) [A61K 35/545 (2013.01); C12N 15/86 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/999 (2013.01); C12N 2502/1114 (2013.01)] 12 Claims
 
1. A method of producing human induced pluripotent stem cells (iPSCs) comprising:
a) contacting and culturing an isolated population of cells comprising γδ T cells with an activation culture to activate and enrich Vγ9Vδ2 γδ T cells within the isolated population of cells; wherein the activation culture comprises IL-15 and zoledronic acid;
b) after step (a), purifying the Vγ9Vδ2-enriched γδ T cells from the isolated population of cells;
c) transducing the purified Vγ9Vδ2-enriched γδ T cells with a viral vector encoding one or more reprogramming factors; and
d) culturing the transduced cells under conditions suitable for reprogramming mammalian somatic cells to a pluripotent state, thereby producing iPSCs;
wherein the produced iPSCs have rearranged TRG and TRD genes;
wherein the produced iPSCs have TCR rearrangements containing Vγ9 and Vδ2 gene segments;
wherein optionally the activation culture further comprises IL-2;
wherein optionally the viral vector is a Sendai virus (SeV) vector;
wherein optionally the method further comprises obtaining the isolated population of cells from a subject prior to step (a); and
wherein optionally the isolated population of cells are peripheral blood mononuclear cells (PBMCs).